At a time when most press coverage of stem cells looked at the ethical controversies surrounding embryonic cens and the potential for them to be used some day as therapies, this story looked at the products, made from adult stem cells, that are already being used to treat people and will be the first to reach the market. Bloomberg reporter Rob Waters examined the science underlying these cells, explained the difference between embryonic and adult cells and looked at the strategies of three companies developing these therapies. By showing how stem cell therapy saved the life of one young child, it provided an advanced look at the potential power of this emerging medical technology.
See the archived story and contest questionnaire about how the story was written.